|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8749
|
|
pubmed:dateCreated |
1991-5-28
|
|
pubmed:abstractText |
In a double-blind study ten asthmatic patients with impaired lung function received the cysteinyl-leukotriene receptor antagonist ICI 204,219 (40 mg by mouth) and placebo in random order on 2 days at least 1 week apart. The increase in forced expiratory volume in 1 s (FEV1) above baseline was significantly greater after ICI 204,219 than after placebo. This effect persisted after nebulised salbutamol. These findings suggest that cysteinyl-leukotrienes are one of the causes of persistent bronchoconstriction in chronic asthma.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
337
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1062-3
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1673495-Administration, Inhalation,
pubmed-meshheading:1673495-Adult,
pubmed-meshheading:1673495-Airway Resistance,
pubmed-meshheading:1673495-Albuterol,
pubmed-meshheading:1673495-Asthma,
pubmed-meshheading:1673495-Bronchoconstriction,
pubmed-meshheading:1673495-Double-Blind Method,
pubmed-meshheading:1673495-Drug Evaluation,
pubmed-meshheading:1673495-Female,
pubmed-meshheading:1673495-Forced Expiratory Volume,
pubmed-meshheading:1673495-Humans,
pubmed-meshheading:1673495-Leukotriene Antagonists,
pubmed-meshheading:1673495-Male,
pubmed-meshheading:1673495-Middle Aged,
pubmed-meshheading:1673495-Tosyl Compounds
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist.
|
|
pubmed:affiliation |
Department of Thoracic Medicine, London Chest Hospital, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
